A supercomputer in the Lawrence Livermore National Laboratory will be used in Project ATOM, a new public-private project that aims to speed discovery of new drug therapies.
A pioneering public/private consortium is poised to turn the marathon of drug discovery into a team relay, maybe even a short one.
Marquitta White (right), MS, PhD, a postdoctoral fellow in the Burchard Lab, took on five young summer research students of diverse backgrounds, including Maria Contreras (left) and Oona Risse-Adams (center), a 16-year-old sophomore at Lowell High School in San Francisco.
The photograph of Martin Luther King Jr. hanging on the wall of the Asthma Collaboratory lab in UC San Francisco’s Rock Hall serves a reminder to all who toil there, purifying DNA samples or analyzing genetic, social or environmental data that their research is also part of a dream of equality and...
Francesca Aweeka, PharmD, a faculty member in the School’s Department of Clinical Pharmacy, will co-lead a new five-year, $3.4 million study funded by the National Institutes of Health (NIH) to address one of the world’s most vexing health problems—preventing malaria, especially in the most...
The U.S. Food and Drug Administration (FDA) is tapping the UCSF School of Pharmacy and Stanford University to launch its first West Coast regulatory science center, focused on spurring innovation in the development and evaluation of safer and more effective medications.
A new analysis of dozens of animal studies evaluating the effects of the cholesterol-lowering statin class of drugs on atherosclerosis found larger positive effects in studies not sponsored by the pharmaceutical industry as compared to those that were industry sponsored.
Every year U.S. drug regulators approve dozens of new medicines as “safe and effective,” but just how effective are they? How well do they alleviate specific aspects of illness, whether light sensitivity from migraine headaches or itching from eczema?
Pharmaceutical companies will increasingly apply the predictive modeling of quantitative pharmacology to do more efficient drug development, says Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department
